Pharmacological therapy for ST-segment elevation myocardial infarction: a review

Novrianti, Irma, Wijaya, Dhani, Mustamin, Faizal and Wijayanti, Sari (2020) Pharmacological therapy for ST-segment elevation myocardial infarction: a review. Journal of Islamic Pharmacy, 5 (2). pp. 9-13. ISSN 2527-6123

Preview

Text 8657.pdf - Published Version Download (877kB) | Preview

Abstract

Coronary Heart Disease (CHD) is the cardiovascular disease due to plaque build-up in the coronary artery, reducing the blood flow to the heart. STEMI (ST-segment elevation myocardial infarction) is the CHD due to the ST-segment elevation in 12 and the cardiac marker elevation as Troponin I. The elevation is due to a blockage in the coronary artery, causing the blood perfusion and oxygen supply for the heart to decrease. We searched the article on internet search engine, and scientific search engines including Scopus and PubMed and collected original articles including Randomized Clinical Trial [RCT], comparative, review article, prospective study, and a guideline about therapy pharmacology of STEMI from 1993 to 2019. The following keywords are used: “Guideline ofSTEMI”, “STEMI” OR “streptokinase” OR “fibrinolytic” OR “Pharmacotherapy of STEMI” OR “PCI”. Conclusion: STEMI therapy management is discomfort management and reperfusion therapy. The reperfusion therapy is aimed to recover the myocardial blood flow, to heal the heart, and to reduce the mortality level. The primary coronary artery reperfusion can be administered with the primary percutaneous coronary intervention (PCI). PCI can open a blockage in the coronary artery and has a good effect on the short-term and long-term clinical results. Besides, it reduces the death risk, myocardial infarction, or repetitive stroke. Meanwhile, reperfusion using fibrinolytics is conducted when PCI is unavailable. Moreover, anticoagulant, antithrombotic, and vasodilators are supporting therapies for STEMI patients to reduce chest pain and prevent reinfarction.

Item Type:	Journal Article
Keywords:	coronary heart disease; STEMI; reperfusion; PCI; fibrinolytics
Subjects:	11 MEDICAL AND HEALTH SCIENCES > 1102 Cardiorespiratory Medicine and Haematology > 110201 Cardiology (incl. Cardiovascular Diseases) 11 MEDICAL AND HEALTH SCIENCES > 1115 Pharmacology and Pharmaceutical Sciences > 111502 Clinical Pharmacology and Therapeutics
Divisions:	Faculty of Medical and Health Sciences > Department of Pharmacy
Depositing User:	apt. Dhani Wijaya
Date Deposited:	21 Jun 2021 05:58

Downloads

Origin of downloads

Actions (login required)

View Item